Literature DB >> 15374965

Microregional effects of gemcitabine in HCT-116 xenografts.

Lynsey A Huxham1, Alastair H Kyle, Jennifer H E Baker, Lani K Nykilchuk, Andrew I Minchinton.   

Abstract

To examine the tumor microregional effects after gemcitabine administration to mice, we mapped the location of proliferating and hypoxic cells relative to vasculature in human colon cancer xenografts. The S-phase marker bromodeoxyuridine was used as a surrogate of drug effect and administered 2 hours before tumor excision, whereas vessel position and perfusion were assessed via staining for CD31 and intravenous injection of carbocyanine, respectively. Hypoxia was detected using pimonidazole. Images of the four markers were overlaid to reveal the spatial relationship between proliferation, vasculature, and hypoxia and to examine the microregional effects. Within 1 day after administration of 240 mg/kg of gemcitabine, proliferation throughout the tumor was completely inhibited. Over time, a reemergence of dividing cells occurred in relation to the distance from vasculature. Microregional analysis revealed that cells located distal to vasculature commenced cycling sooner than cells located proximal to vasculature. A similar trend was seen after multiple doses of gemcitabine (40 mg/kg on days 1, 4, 7, and 10). The possibility that the effect of gemcitabine could be attributed to changes in oxygenation was discounted after examining the vessel perfusion and patterns of hypoxia. The effect of gemcitabine was examined in multilayered cell culture, and at doses <30 micromol/L, a gradient in proliferation between the exposed and unexposed sides was observed. We show a differential effect on cell proliferation in relation to vasculature and conclude that cells distal to blood vessels are less affected by gemcitabine probably because of limited penetration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374965     DOI: 10.1158/0008-5472.CAN-04-0986

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

2.  Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.

Authors:  Xinjian Mao; Sarah McManaway; Jagdish K Jaiswal; Cho R Hong; William R Wilson; Kevin O Hicks
Journal:  Cancer Biol Ther       Date:  2019-05-26       Impact factor: 4.742

3.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

4.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

5.  An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.

Authors:  Foster C Gonsalves; Keren Klein; Brittany B Carson; Shauna Katz; Laura A Ekas; Steve Evans; Robert Nagourney; Timothy Cardozo; Anthony M C Brown; Ramanuj DasGupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-10       Impact factor: 11.205

6.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

7.  Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy.

Authors:  Sylvine Cottin; Karim Ghani; Pedro Otavio de Campos-Lima; Manuel Caruso
Journal:  Mol Cancer       Date:  2010-06-10       Impact factor: 27.401

8.  Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

Authors:  K K Y Cham; J H E Baker; K S Takhar; J A Flexman; M Q Wong; D A Owen; A Yung; P Kozlowski; S A Reinsberg; E M Chu; C-W A Chang; A K Buczkowski; S W Chung; C H Scudamore; A I Minchinton; D T T Yapp; S S W Ng
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel.

Authors:  Andrea S Fung; James Jonkman; Ian F Tannock
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

10.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Authors:  Krupa J Patel; Ian F Tannock
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.